Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Melinta Therapeutics

Melinta Therapeutics
2000 FOUNDED
PUBLIC STATUS
201-300 EMPLOYEES
MLNT STOCK SYMBOL
2 INVESTMENTS
$4.16 SHARE PRICE (As of Tuesday Closing)
Description

Melinta Therapeutics Inc is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications.

Website
Formerly Known As
Rib-X Pharmaceuticals, Rib-X Designs
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 300 George Street
  • Suite 301
  • New Haven, CT 06511
  • United States

+1 (312) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Melinta Therapeutics’s full profile, request a free trial.

Melinta Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.62 - $20.00 $57.2M $3.92 -$11.86 458K 13.8M

Melinta Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 121,826 69,588 181,839 (85,282)
Revenue 99,606 96,430 33,864 0
EBITDA (79,186) (97,842) (50,996) (69,059)
Net Income (134,692) (157,192) (58,916) (73,932)
Total Assets 440,372 441,590 160,273 16,634
Total Debt 162,551 110,476 39,555 69,899
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Melinta Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Melinta Therapeutics‘s full profile, request access.

Request full access to PitchBook

Melinta Therapeutics Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Achaogen Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
0000000000 0000000 Formerly VC-backed Watertown, MA 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Vienna, Austria 000 00000 00000000000 00000
00000000 Formerly VC-backed Allschwil, Switzerland 000 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Melinta Therapeutics Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 0000 05-Jan-2018 000000000000000000 00000 Drug Discovery 000000 00000000
Cempra Pharmaceuticals 03-Nov-2017 Merger/Acquisition Pharmaceuticals 0000 000000
To view this company’s complete investment and acquisition history, request access »

Melinta Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Melinta Therapeutics‘s full profile, request access.

Request full access to PitchBook

Melinta Therapeutics Executive Team (19)

Name Title Board
Seat
Contact
Info
Sue Cammarata MD Chief Medical Officer & Executive Vice President
Peter Moore Ph.D Co-Founder
Thomas Steitz Ph.D Co-Founder
William Jorgensen Ph.D Co-Founder
Lyn Baranowski Senior Vice President, Corporate Development and Strategy

12 Former Executives

You’re viewing 5 of 19 executives. Get the full list »

Melinta Therapeutics Board Members (23)

Name Representing Role Since Contact
Info
Bruce Downey JD Self Board Member 000 0000
Cecilia Gonzalo Vatera Healthcare Partners Board Member 000 0000
Christopher Kiritsy Self Board Member 000 0000
David Zaccardelli Self Board Member 000 0000
Erik Akhund Self Board Member 000 0000

13 Former Board Members

You’re viewing 5 of 23 board members. Get the full list »